MDCO Key Stats
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavis May 18
- MEDICINES CO /DE Financials May 17
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Pric... May 16
- Why The Medicines Company May Be About to Take Off Fool May 16
- The Medicines Company CEO Presents at Bank of America Merrill Lynch 2013 Health ... May 15
- Pediatric Approval for MDCO/BMY's Recothrom May 15
- Pediatric Approval for MDCO/BMY's Recothrom - Analyst Blog Zacks May 15
- Actavis Joins Other Drugmakers On Elite IBD 50 May 11
- Stocks Hitting 52-Week Highs Benzinga May 10
- MEDICINES CO /DE Files SEC form 10-Q, Quarterly Report May 10
MDCO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Medicines is up 67.65% over the last year vs S&P 500 Total Return up 30.71%, Warner Chilcott up 27.49%, and Acura Pharmaceuticals down 10.31%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for MDCO
Pro Report PDF for MDCO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download MDCO Pro Report PDF
Pro Strategies Featuring MDCO
Did Medicines make it into our Pro Portfolio Strategies?
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics Corporation, The Medicines Company’s pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic in late-stage development in the United States. The Medicines Company was founded by Clive A. Meanwell and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, New Jersey.